Pharmacokinetics of Maraviroc and Boosted Atazanavir Dual Regimen in Stable HIV-infected Patients
Status:
Withdrawn
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to describe pharmacokinetics of maraviroc (MVC) 300 mg and
atazanavir/ritonavir (ATV/r) 200/100 mg QD in HIV-infected stable patients.